Abstracts tagged "Anakinra"

Abstract Number: 0196 • ACR Convergence 2021
A Single Center, Double Blind, Randomized, Placebo-Controlled Trial of Anakinra in Adult Patients with Features of Cytokine Storm Syndrome in COVID-19
Lesley Jackson¹, Randy Cron¹, Nitasha Khullar², Christopher Chapleau³, Dongmei Sun⁴ and Winn Chatham¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama Birmingham, Birmingham, AL, ³UAB Pharmacy, University of Alabama at Birmingham, Birmingham, AL, ⁴Division of Clinical Immunology and Rheumatology, The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Some patients with COVID-19 develop respiratory distress and cytokine storm syndrome (CSS) which is characterized by hyperinflammation and may progress to multi-organ failure. Anakinra…
Abstract Number: 010 • 2020 Pediatric Rheumatology Symposium
Experience with and Management of HLH-like Toxicities Following Chimeric Antigen Receptor T-Cell Therapy for Treatment of Relapsed/Refractory Pre-B ALL
Amanda Ombrello¹, Bonnie Yates ², Haneen Shalabi ², Terry Fry ³ and Nirali Shah ², ¹National Human Genome Research Institute/National Institutes of Health, Bethesda, ²National Cancer Institute/National Institutes of Health, Bethesda, ³University of Colorado, Denver/Children's Hospital Colorado, Denver
Background/Purpose: Chimeric antigen receptor T-cell (CAR-T) therapy is a highly effective form of adoptive cell immunotherapy combining antigen specific targeting capabilities with T-cell based cytotoxicity.…
Abstract Number: 028 • 2020 Pediatric Rheumatology Symposium
A Randomized, Double-blind, Placebo-controlled Study of Anakinra in Pediatric and Adult Patients with Still’s Disease
Laura Schanberg¹, Peter Nigrovic ², Ashley Cooper ³, Winn Chatham ⁴, Shoghik Akoghlanian ⁵, Namrata Singh ⁶, C. Egla Rabinovich ⁷, Akaluck Thatayatikom ⁸, Alysha Taxter ⁹, Jonathan Hausmann ¹⁰, Milan Zdravkovic ¹¹, Sven Ohlman ¹¹, Henrik Andersson ¹¹, Susanna Cederholm ¹², Gunilla Huledal ¹¹, Rayfel Schneider ¹³ and Fabrizio De Benedetti ¹⁴, ¹Duke Children's Hospital & Health Center, Durham, North Carolina, ²Boston Children's Hospital, Boston, Massachusetts, ³Children's Mercy Kansas City, Kansas City, ⁴University of Alabama at Birmingham, Birmingham, ⁵Nationwide Children's Hospital, Columbus, ⁶University of Iowa Hospitals and Clinics, Iowa, Iowa, ⁷Duke University Hospital, Durham, ⁸University of Florida, Gainesville, ⁹Wake Forest Baptist Medical Center, Winston-Salem, ¹⁰Division of Immunology, Boston Children's Hospital; Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, ¹¹Sobi, Stockholm, Sweden, ¹²Stockholm, Sweden, ¹³The Hospital for Sick Children, Toronto, Canada, ¹⁴Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy
Background/Purpose: Adult-onset Still’s disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA) are rare systemic disorders of auto-inflammatory nature. There is a growing understanding that SJIA…
Abstract Number: 098 • 2020 Pediatric Rheumatology Symposium
Early Treatment with Anakinra in Systemic Juvenile Idiopathic Arthritis
Manuela Pardeo¹, Claudia Bracaglia ¹, Emanuela Sacco ¹, Denise Pires Marafon ¹, Antonella Insalaco ¹, Giulia Marucci ¹, Rebecca Nicolai ², Virginia Messia ¹ and Fabrizio De Benedetti ¹, ¹Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy, ²IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) should be considered as a polygenic autoinflammatory disease. Interleukin 1 (IL-1) has been shown to be a major mediator…
Abstract Number: 099 • 2020 Pediatric Rheumatology Symposium
Reversible Hepatotoxicity to IL-1/IL-6 Blockade in Pediatric Patients with Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome
Omkar Phadke¹, Sampath Prahalad ² and Kelly Rouster-Stevens ³, ¹EMORY, Atlanta, Georgia, ²Emory + Children's Pediatric Institute, Atlanta, ³Emory University/Children's Healthcare of Atlanta, Atlanta, Georgia
Background/Purpose: Treatment for systemic JIA (sJIA) complicated by macrophage activation syndrome (MAS) may involve blockade of IL-1 and IL-6. There are reports of adults with…
Abstract Number: 100 • 2020 Pediatric Rheumatology Symposium
Does Anakinra Dampen Neuronal Damage in Children with Febrile-Infection Related Epilepsy Syndrome (FIRES): A Single Center Review of Neuroimaging
Eyal Muscal¹, Jill Hunter ², Yi-Chen Lai ² and James Riviello ², ¹Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, houston, ²BCM/TCH, Houston
Background/Purpose: Febrile-illness related epilepsy syndrome (FIRES), characterized by the emergence of super refractory status epilepticus (SRSE) in previously healthy children following a febrile illness, is…
Abstract Number: 354 • 2019 ACR/ARP Annual Meeting
Evaluation of Opioid Analgesia in Hospitalized Patients with Acute Crystal Induced Arthritis
Sukhraj Singh¹, Anthony Ocon ¹, Mark Riley ², Jennifer Tchervenkov ¹ and Ruben Peredo-Wende ¹, ¹Albany Medical Center, Albany, NY, ²Albany Medical Center, Albany
Background/Purpose: The Opioid Epidemic has been declared a public health emergency since 2017. The use of opioids in the acute crystal induced arthritis (ACIA) population…
Abstract Number: 800 • 2019 ACR/ARP Annual Meeting
Cryopyrin-Associated Periodic Syndrome in Korea: 19 Years of Experience
Young Ho Kim¹, Bongjik Kim ², Byung Yoon Choi ², Haeng Jin Lee ³, Dae-Chul Jeong ⁴, Jinhee Han ², Hye-Rim Park ², Jayoung Oh ², Seungmin Lee ², Dooyi Oh ⁵ and Soyoung Lee ¹, ¹Department of Pediatrics, Seoul National University Children's Hospital, Seoul, Seoul-t'ukpyolsi, Republic of Korea, ²Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University Bundang Hospital, Seongnam, Kyonggi-do, Republic of Korea, ³Department of Ophthalmology, Seoul National University Hospital, Seoul, Republic of Korea, ⁴Department of Pediatrics, The Catholic University of Korea, Seoul, Seoul-t'ukpyolsi, Republic of Korea, ⁵Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University Bundang Hospital, Seoul, Kyonggi-do, Republic of Korea
Background/Purpose: Cryopyrin-associated periodic syndrome (CAPS) is rare auto-inflammatory disorder characterized by recurrent episodes fever with variable manifestation of systemic inflammation such as urticarial skin rash,…
Abstract Number: 801 • 2019 ACR/ARP Annual Meeting
Preliminary Analysis of Hearing Loss in a Neonatal-Onset Multisystem Inflammatory Disease (NOMID) Cohort Followed over a Mean of 10 Years: Normal Hearing at Baseline and Early Treatment with Anakinra Area Associated with Maintenance of Normal Hearing
Sara Alehashemi¹, Megha Garg ², Kelly King ³, Chris Zalewski ³, Adriana de Jesus ⁴, John Butman ⁵, Jonah Eisenberg ⁶, Carmen Brewer ³, Jeffrey KIm ⁷ and Raphaela Goldbach-Mansky ¹, ¹Translational Autoinflammatory Diseases Section/NIAID/NIH, Bethesda, MD, ²Rochester Regional Health, Rochester, NY, ³NIDCD/NIH, Bethesda, ⁴Translation Autoinflammatory Diseases Section/NIAID/NIH, Silver Spring, MD, ⁵CC/NIH, Bethesda, ⁶University of Michigan, Ann Arbor, ⁷NIDCD, Bethesda
Background/Purpose: Neonatal-onset multisystem inflammatory disease (NOMID), caused by gain-of-function mutation in the NLRP3 inflammasome, presents with systemic inflammation, rash, eye inflammation, aseptic meningitis and sensorineural…
Abstract Number: 1240 • 2019 ACR/ARP Annual Meeting
A Randomized, Phase 2 Study Evaluating the Efficacy and Safety of Anakinra in Difficult-To-Treat Acute Gouty Arthritis: The anaGO Study
Kenneth Saag¹, Alexander So ², Puja Khanna ³, Robert Keenan ⁴, Sven Ohlman ⁵, Torbjörn Kullenberg ⁵, Lisa Osterling Koskinen ⁵, Michael Pillinger ⁶ and Robert Terkeltaub ⁷, ¹University of Alabama at Birmingham, Birmingham, AL, ²Université de Lausanne, Lausanne, Switzerland, ³University of Michigan Medical School, Ann Arbor, ⁴Duke University School of Medicine, Durham, ⁵Sobi, Stockholm, Sweden, ⁶New York University School of Medicine, New York, ⁷San Diego VA/UCSD, San Diego, CA
Background/Purpose: In gout, urate crystals deposited in and around joints trigger episodes of acute arthritis, mediated by the proinflammatory cytokine IL-1β. In uncontrolled studies, the…
Abstract Number: 2695 • 2019 ACR/ARP Annual Meeting
Early Treatment with Anakinra in Systemic Juvenile Idiopathic Arthritis
Manuela Pardeo¹, Claudia Bracaglia ², Anna Tulone ³, Antonella Insalaco ¹, Giulia Marucci ¹, Rebecca Nicolai ³, Virginia Messia ¹, Emanuela Sacco ⁴ and Fabrizio De Benedetti ⁵, ¹Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, ²Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ³Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Lazio, Italy, ⁴Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, ⁵Bambino Gesù Children’s Hospital, Rome, Italy
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) accounts for 10-20% of all patients with JIA. sJIA should be considered as a polygenic autoinflammatory disease. Interleukin 1…
Abstract Number: 1295 • 2018 ACR/ARHP Annual Meeting
Anakinra Is More Effective at Reducing Pain from Acute Crystal Induced Arthritis When Compared to Conventional Therapy: A Retrospective Review at a Tertiary Care Center
Sukhraj Singh¹, Anthony Ocon², Vivek Mehta³, Samah Musa¹ and Ruben Peredo², ¹Internal Medicine, Albany Medical Center, Albany, NY, ²Medicine, Albany Medical Center, Albany, NY, ³Division of Rheumatology, Department of Medicine, Albany Medical College, Albany, NY
Background/Purpose: The management of Acute Crystal-Induced Arthritis (ACIA) relies on NSAIDs, colchicine, and glucocorticoids as conventional therapy. In presence of comorbidities (e.g. renal insufficiency, diabetes…
Abstract Number: 1414 • 2018 ACR/ARHP Annual Meeting
Pharmacovigilance of Biologics for Systemic Juvenile Idiopathic Arthritis Patients By the German Biologics Registry
Gerd Horneff¹, Gerd Ganser², Toni Hospach³, Ivan Foeldvari⁴, Michael Borte⁵, Frank Weller-Heinemann⁶, Kirsten Minden⁷ and Ariane Klein⁸, ¹Asklepios Kinderklinik St. Augustin GmbH, Sankt Augustin, Germany, ²Klinik für Kinder-und Jugendrheumatologie, Nordwestdeutsches Rheumazentrum, Sendenhorst, Germany, ³Pediatrics, Olgahospital, Klinikum Stuttgart, Stuttgart, Germany, ⁴Hamburg Centre for Pediatric Rheumatology, Hamburg, Germany, ⁵St Georg Hospital, Leipzig, Germany, ⁶PRINTO, Genoa, Italy, ⁷Charité–Universitätsmedizin Berlin, Berlin, Germany, ⁸Center of Pediatrics and Neonatology, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany
Background/Purpose: Long-term surveillance of biologic drugs is particularly important in pediatric patients(pts). Since 2001, the German Biologics JIA Registry (BIKER) is allowing to follow up…
Abstract Number: 2218 • 2018 ACR/ARHP Annual Meeting
Use of Anakinra in Hospitalized Patients with Acute Crystalline Arthritis
Jean Liew and Gregory Gardner, Rheumatology, University of Washington, Seattle, WA
Background/Purpose: Medically complex individuals may have contraindications to standard therapies for acute arthritis secondary to gout or calcium pyrophosphate disease (CPPD). Observational studies have demonstrated…
Abstract Number: 2975 • 2018 ACR/ARHP Annual Meeting
Anti-Il-1 Therapies in Patients with Familial Mediterranean Fever Related AA-Amyloidosis
Bilgesu Ergezen¹, Serdal Ugurlu², Oguzhan Selvi³, Bugra Han Egeli⁴ and Huri Ozdogan³, ¹Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ²Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ³Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ⁴Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey
Background/Purpose: The most devastating complication of Familial Mediterranean Fever is secondary AA amyloidosis and is still a problem in many cases. Efforts have been paid…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].